| Literature DB >> 23936042 |
Ping Liu1, Jianwen Song, Hui Su, Linli Li, Ning Lu, Rongli Yang, Zhenhui Peng.
Abstract
BACKGROUND: A number of observational studies have been conducted to investigate the association of the IL-10 gene polymorphisms with systemic lupus erythematosus (SLE) susceptibility. However, their results are conflicting.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23936042 PMCID: PMC3720721 DOI: 10.1371/journal.pone.0069547
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow diagram of the study selection process.
Characteristics of included studies in this meta-analysis.
| Study | Ref. | Ethnicity | Country | SLE | Control | Genotype method | Studied polymorphisms | Findings |
| Eskdale (1997) | 1 | Caucasian | UK | 56 | 102 | Genescan | IL10.G, IL10.R | CA21, CA25 associated with SLE |
| Lazarus (1997) | 2 | Caucasian | UK | 76 | 119 | ASO | −1082, −819, −592 | No association |
| Mehrian (1998) | 3 | Mexican | USA | 158 | 220 | Genescan | IL10.G | CA22, CA23 associated with SLE (P = 0.0001, P = 0.015, respectively) |
| Mok (1998) | 4 | Asian | China | 88 | 83 | RFLP | −1082, −819, −592 | No association |
| Ou (1998) | 5 | Asian | China | 100 | 103 | Genescan | IL10.G | No association |
| Alarcon-Riquelme (1999) | 6 | Mexican | Mexico | 330 | 368 | Genescan | IL10.G | No association |
| Crawley (1999) | 7 | Caucasian | UK | 120 | 274 | ASO | −1082, −819, −592 | No association |
| Rood (1999) | 8 | Caucasian | Netherlands | 92 | 162 | ASO | −1082, −819, −592 | No association |
| D'Alfonso 1 (2000) | 9 | Caucasian | Italy | 98 | 104 | Genescan | IL10.G, IL10.R | CA23 associated with SLE (P = 0.0425) |
| D'Alfonso 2 (2000) | 10 | Caucasian | Italy | 68 | 64 | Genescan | IL10.G | CA23 associated with SLE (P = 0.0470) |
| Gibson (2002) | 11 | African | USA | 60 | 64 | Sequencing | −3575, −2849, −2763 | −2763 associated with SLE (P<0.05) |
| D'Alfonso (2002) | 12 | Caucasian | Italy | 205 | 631 | HPLC | 26 SNPs including −1082, −592, −3575,−2849 | IL10G long alleles (CA repeat >21) associated with SLE |
| Dijstelbloem (2002) | 13 | Caucasian | Netherlands | 180 | 163 | ASO | −1082 | No association |
| Guseva (2003) | 14 | Kazakh | Russia | 49 | 71 | PCR-SSP | −592 | −592 associated with SLE (P = 0.003) |
| Shen (2003) | 15 | Asian | China | 220 | 230 | Genescan, PCR-SSP | IL10G, IL10R, −1082, −819, −592 | CA21, CA22, −1082 associated with SLE (P = 0.009, 0.006 and <0.0001, respectively) |
| Chong (2004) | 16 | Asian | China | 554 | 708 | Genescan, Taqman,RFLP | IL10.G, IL10.R | −592, CA16 associated with SLE (0.009 and 0.017, respectively) |
| Fei (2004) | 17 | Caucasian | Sweden | 52 | 26 | RFLP | −1082 | −1082 associated with SLE (P<0.05) |
| Schotte (2004) | 18 | Caucasian | Germany | 210 | 158 | Genescan | IL10.G, IL10.R | No association |
| Guzowski (2005) | 19 | Mixed | USA | 48 | 25 | HPLC | −1082, −819, −592 | Not estimate |
| Hrycek (2005) | 20 | Caucasian | Poland | 24 | 36 | PCR-SSP | −1082, −819, −592 | No association |
| Khoa (2005) | 21 | Asian | Vietnam | 64 | 57 | PCR-SSP | −1082 | −1082 associated with SLE (P<0.05) |
| Lu (2005) | 22 | Asian | China | 136 | 115 | RFLP | −819 | −819 associated with SLE (P = 0.009) |
| Suarez (2005) | 23 | Caucasian | Spain | 187 | 343 | ASO | −1082, −592 | No association |
| Zhu (2005) | 24 | Asian | China | 265 | 100 | RFLP | −592 | No association |
| Chen (2006) | 25 | Asian | China | 237 | 304 | Genescan | IL10.G | CA20 associated with SLE (P<0.0001) |
| Hirankarn (2006) | 26 | Asian | Thailand | 195 | 159 | MS | −1082, −819, −592 | Haplotype ACC associated with SLE (P = 0.03) |
| Sung (2006) | 27 | Asian | Korea | 350 | 330 | SNaPshot | 9 SNPs including −1082, −819, −592 | No association |
| Guarnizo-Zuccardi (2007) | 28 | Colombian | Colombia | 120 | 102 | PCR-SSP | −1082, −819, −592 | No association |
| Lin (2007) | 29 | Asian | China | 119 | 100 | RFLP | −592 | −592 associated with SLE (P = 0.003) |
| Lan (2007) | 30 | Asian | China | 90 | 110 | RFLP | −1082, −819, −592 | −1082 and haplotype GCC associated with SLE (P<0.05) |
| Wang (2007) | 31 | Asian | China | 83 | 125 | RFLP | −1082, −819, −592 | −819, −592, haplotype ACC, haplotype ATA associated with SLE (P<0.001) |
| Xu (2007) | 32 | Asian | China | 103 | 110 | RFLP | −3575, −2763 | −3575 associated with SLE (P<0.05) |
| Zhou (2007) | 33 | Asian | China | 137 | 122 | RFLP | −1082, −819, −592 | −1082 and associated with SLE (P<0.001) |
| Hee (2008) | 34 | Asian | Malaysia | 44 | 44 | RFLP | −1082, −819, −592 | haplotype GCC associated with SLE (P = 0.004) |
| Miyagawa (2008) | 35 | Asian | Japan | 264 | 695 | PLACE-SSCP | 5 SNPs including −819, −592 | No association |
| Rosado (2008) | 36 | Caucasian | Spain | 116 | 151 | Genescan, RFLP | IL10G, IL10R, −1082, −819, −592 | Haplotype GCC, ACC (P<0.05) |
| Gateva (2009) | 37 | Caucasian | USA, Sweden | 1963 | 4329 | SNP array | Over 12000 variants | rs3024505 (P = 3.95×10−8) |
| Sobkowiak (2009) | 38 | Caucasian | Poland | 103 | 300 | Sequencing | −1082, −819, −592 | Haplotype GCC (P = 0.0022) |
| Lin (2010) | 39 | Asian | China | 172 | 215 | Taqman | −1082, −819, −592 | Haplotype ATA (P<0.001) |
| Miteva (2010) | 40 | Caucasian | Bulgaria | 157 | 126 | PCR-SSP | −1082 | No association |
| Yu (2010) | 41 | Asian | China | 110 | 138 | SNPstream | −1082, −819, −592 | No association |
| Ren (2011) | 42 | Asian | China | 145 | 80 | RFLP | −592 | No association |
ASO: allele-specific oligonucleotid hybridization; RFLP: restriction fragment length polymorphism; PCR-SSP: polymerase chain reaction sequence specific primer; HPLC: high-performance liquid chromatography; MS: mass spectrometry; PLACE-SSCP post-PCR fluorescent labeling and automated capillary electrophoresis under single-strand conformation polymorphism conditions; SNPs: single nucleotide polymorphisms.
no polymorphisms.
Meta-analysis of the IL-10.G and IL-10.R microsatellites with SLE.
| Genetic model | Population | Study | OR (95% CI) | Statistical model | I2 |
|
|
| IL-10.G CA21 | Overall | 10 | 1.03 (0.85–1.25) | Random | 77.0% | <0.001 | 0.512 |
| Caucasian | 4 | 0.86 (0.62–1.20) | Random | 58.9% | 0.063 | 0.327 | |
| Mexican | 2 | 0.84 (0.42–1.76) | Random | 92.9% | <0.001 | – | |
| Asian | 4 |
| Random | 67.4% | 0.027 | 0.199 | |
| IL-10.G CA22 | Overall | 10 | 1.10 (0.83–1.45) | Random | 72.1% | <0.001 | 0.352 |
| Caucasian | 4 | 1.33 (0.88–1.99) | Fixed | 0.0% | 0.947 | 0.170 | |
| Mexican | 2 | 1.59 (0.54–4,69) | Random | 94.2% | <0.001 | – | |
| Asian | 4 | 0.86 (0.73–1.01) | Fixed | 45.8% | 0.137 | 0.829 | |
| IL-10.G CA23 | Overall | 10 | 1.18 (0.88–1.57) | Random | 41.5% | 0.081 | 0.555 |
| Caucasian | 4 | 1.30 (0.76–2.25) | Random | 61.8% | 0.049 | 0.770 | |
| Mexican | 2 | 1.22 (0.88–1.70) | Fixed | 62.8% | 0.101 | – | |
| Asian | 4 | 0.96 (0.61–1.49) | Fixed | 25.2% | 0.260 | 0.371 | |
| IL-10.G CA24 | Overall | 10 | 0.84 (0.68–1.03) | Fixed | 5.9% | 0.387 | 0.798 |
| Caucasian | 4 | 0.93 (0.51–1.69) | Random | 54.5% | 0.086 | 0.484 | |
| Mexican | 2 | 0.87 (0.63–1.20) | Fixed | 0.0% | 0.452 | – | |
| Asian | 4 | 0.77 (0.54–1.11) | Fixed | 0.0% | 0.551 | 0.267 | |
| IL-10.G CA25 | Overall | 10 | 0.77 (0.58–1.03) | Random | 77.2% | <0.001 | 0.490 |
| Caucasian | 4 | 0.54 (0.27–1.05) | Random | 87.8% | <0.001 | 0.577 | |
| Mexican | 2 | 1.00 (0.78–1.28) | Fixed | 0.0% | 0.646% | – | |
| Asian | 4 | 0.92 (0.74–1.13) | Fixed | 1.8% | 0.383 | 0.710 | |
| IL-10.G CA26 | Overall | 10 | 1.04 (0.89–1.22) | Fixed | 0.0% | 0.816 | 0.369 |
| Caucasian | 4 | 1.11 (0.77–1.61) | Fixed | 0.0% | 0.763 | 0.968 | |
| Mexican | 2 | 0.88 (0.62–1.23) | Fixed | 0.0% | 0.350 | – | |
| Asian | 4 | 1.08 (0.89–1.32) | Fixed | 0.0% | 0.582 | 0.147 | |
| IL-10.G CA27 | Overall | 10 |
| Fixed | 8.2% | 0.366 | 0.561 |
| Caucasian | 4 |
| Fixed | 0.0% | 0.785 | 0.536 | |
| Mexican | 2 | 1.22 (0.83–1.79) | Fixed | 56.5% | 0.129 | – | |
| Asian | 4 | 1.23 (0.82–1.86) | Fixed | 35.0% | 0.201 | 0.213 | |
| IL-10.G CA28 | Overall | 9 | 1.06 (0.72–1.58) | Fixed | 0.5% | 0.429 | 0.839 |
| Caucasian | 3 | 1.03 (0.25–4.22) | Fixed | 0.0% | 0.699 | – | |
| Mexican | 2 | 0.67 (0.28–1.57) | Fixed | 0.0% | 0.542 | – | |
| Asian | 4 | 1.24 (0.77–2.01) | Fixed | 46.8% | 0.130 | 0.946 | |
| IL-10.G Long allele | Overall | 10 | 0.85 (0.64–1.12) | Random | 88.5% | <0.001 | 0.300 |
| Caucasian | 4 | 0.64 (0.28–1.45) | Random | 93.1% | <0.001 | 0.392 | |
| Mexican | 2 | 1.25 (0.57–2.75) | Random | 94.7% | <0.001 | – | |
| Asian | 4 | 0.86 (0.68–1.10) | Random | 70.3% | 0.018 | 0.322 | |
| IL-10.R R2 | Caucasian | 3 | 0.97 (0.77–1.23) | Random | 63.9% | 0.063 | 0.415 |
| IL-10.R R3 | Caucasian | 3 | 1.00 (0.67–1.50) | Random | 60.9% | 0.077 | 0.308 |
| IL-10.R R4 | Caucasian | 3 | 0.85 (0.38–1.89) | Fixed | 0.0% | 0.443 | 0.702 |
OR: odds ratio; CI: confidence interval; SLE: systemic lupus erythematosus.
Meta-analysis of the IL10 −1082G/A polymorphism and SLE.
| Genetic model | Population | Study | OR (95% CI) | Statistical model | I2 |
|
|
| G vs. A | Overall | 23 | 1.13 (0.92–1.37) | Random | 78.5% | <0.001 | 0.628 |
| 21 |
| Random | 69.2% | <0.001 | 0.797 | ||
| 20 |
| Fixed | 26.4% | 0.135 | 0.299 | ||
| Caucasian | 10 |
| Fixed | 28.3% | 0.184 | 0.885 | |
| 9 |
| Fixed | 33.8% | 0.147 | 0.996 | ||
| Asian | 11 | 1.08 (0.65–1.81) | Random | 88.6% | <0.001 | 0.558 | |
| 10 | 1.28 (0.84–1.95) | Random | 80.0% | <0.001 | 0.185 | ||
| 9 | 1.19 (0.98–1.44) | Fixed | 32.1% | 0.161 | 0.076 | ||
| GG vs. AA | Overall | 15 | 1.24 (0.82–1.86) | Random | 66.9% | <0.001 | 0.608 |
| 13 |
| Fixed | 34.7% | 0.104 | 0.892 | ||
| Caucasian | 9 |
| Fixed | 33.5% | 0.150 | 0.877 | |
| 8 |
| Fixed | 40.4% | 0.109 | 0.830 | ||
| Asian | 4 | 0.99 (0.10–9.75) | Random | 87.1% | <0.001 | – | |
| 3 |
| Fixed | 18.4% | 0.294 | – | ||
| GG+GA vs. AA | Overall | 17 | 1.07 (0.89–1.28) | Random | 61.7% | <0.001 | 0.434 |
| 15 |
| Fixed | 0.0% | 0.610 | 0.501 | ||
| Caucasian | 9 |
| Fixed | 0.0% | 0.749 | 0.982 | |
| 8 |
| Fixed | 0.0% | 0.706 | 0.838 | ||
| Asian | 6 | 0.93 (0.51–1.69) | Random | 84.7% | <0.001 | 0.948 | |
| 5 | 1.26 (0.99–1.62) | Fixed | 24.2% | 0.260 | 0.560 | ||
| GG vs. AA+GA | Overall | 15 | 1.14 (0.81–1.61) | Random | 66.1% | <0.001 | 0.804 |
| 13 | 1.30 (0.94–1.78) | Random | 50.6% | 0.019 | 0.907 | ||
| Caucasian | 9 | 1.22 (0.89–1.67) | Random | 56.1% | 0.020 | 0.911 | |
| 8 | 1.22 (0.85–1.76) | Random | 61.5% | 0.011 | 0.924 | ||
| Asian | 4 | 1.18 (0.22–6.27) | Random | 82.2% | 0.001 | – | |
| 3 |
| Fixed | 4.7% | 0.350 | – |
OR: odds ratio; CI: confidence interval; SLE: systemic lupus erythematosus.
exclude the studies deviating from Hardy-Weinberg equilibrium.
exclude the study by Shen (2003).
Meta-analysis of the IL10 −819C/T polymorphism and SLE.
| Genetic model | Population | Study | OR (95% CI) | Statistical model | I2 |
|
|
| C vs. T | Overall | 18 | 0.91 (0.75–1.10) | Random | 73.5% | <0.001 | 0.232 |
| 14 | 0.90 (0.72–1.11) | Random | 71.7% | <0.001 | 0.107 | ||
| 13 | 1.04 (0.93–1.17) | Fixed | 11.5% | 0.330 |
| ||
| Caucasian | 6 | 0.95 (0.80–1.13) | Fixed | 0.0% | 0.700 | 0.138 | |
| Asian | 10 | 0.94 (0.69–1.28) | Random | 84.6% | <0.001 | 0.580 | |
| 7 | 0.91 (0.62–1.33) | Random | 85.4% | <0.001 | 0.356 | ||
| 6 | 1.15(0.99–1.34) | Fixed | 3.7% | 0.393 | 0.142 | ||
| CC vs. TT | Overall | 13 | 0.87 (0.66–1.16) | Fixed | 29.0% | 0.154 |
|
| 9 | 0.93 (0.65–1.33) | Fixed | 0.0% | 0.734 | 0.165 | ||
| Caucasian | 6 | 0.90 (0.59–1.37) | Fixed | 0.0% | 0.712 | 0.449 | |
| Asian | 5 | 1.09 (0.71–1.68) | Fixed | 47.7% | 0.105 |
| |
| 2 | 1.27 (0.62–2.64) | Fixed | 0.0% | 0.482 | – | ||
| CC+CT vs. TT | Overall | 13 | 0.89 (0.63–1.25) | Random | 59.0% | 0.004 | 0.647 |
| 9 | 0.97 (0.72–1.31) | Fixed | 0.0% | 0.799 | 0.128 | ||
| Caucasian | 6 | 0.91 (0.60–1.37) | Fixed | 0.0% | 0.712 | 0.629 | |
| Asian | 5 | 1.04 (0.59–1.81) | Random | 81.1% | <0.001 | 0.569 | |
| 2 | 1.12 (0.70–1.81) | Fixed | 0.0% | 0.398 | – | ||
| CC vs. TT+CT | Overall | 13 | 0.94 (0.79–1.13) | Fixed | 0.0% | 0.511 | 0.141 |
| 9 | 0.94 (0.77–1.15) | Fixed | 0.0% | 0.665 | 0.291 | ||
| Caucasian | 6 | 0.94 (0.76–1.17) | Fixed | 0.0% | 0.679 | 0.146 | |
| Asian | 5 | 1.05 (0.69–1.59) | Fixed | 27.0% | 0.241 |
| |
| 2 | 1.23 (0.63–2.42) | Fixed | 0.0% | 0.657 | – |
OR: odds ratio; CI: confidence interval; SLE: systemic lupus erythematosus.
exclude the studies deviating from Hardy-Weinberg equilibrium.
exclude the study by Wang (2007).
Meta-analysis of the IL10 −592C/A polymorphism and SLE.
| Genetic model | Population | Study | OR (95% CI) | Statistical model | I2 |
|
|
| C vs. A | Overall | 24 | 0.87 (0.74–1.01) | Random | 76.0% | <0.001 |
|
| 21 |
| Random | 76.4% | <0.001 | 0.104 | ||
| Caucasian | 8 | 1.02 (0.89–1.16) | Fixed | 5.6% | 0.387 | 0.247 | |
| Asian | 13 | 0.85 (0.67–1.09) | Random | 84.5% | <0.001 | 0.120 | |
| 11 | 0.80 (0.60–1.07) | Random | 84.5% | <0.001 | 0.407 | ||
| CC vs. AA | Overall | 18 | 0.72 (0.48–1.07) | Random | 69.1% | <0.001 |
|
| 15 |
| Random | 59.6% | 0.002 | 0.221 | ||
| Caucasian | 7 | 1.08 (0.75–1.55) | Fixed | 0.0% | 0.483 | 0.223 | |
| Asian | 8 | 0.71 (0.36–1.39) | Random | 81.6% | <0.001 | 0.068 | |
| 6 | 0.51 (0.24–1.06) | Random | 72.5% | 0.003 | 0.599 | ||
| CC+CA vs. AA | Overall | 18 |
| Random | 50.4% | 0.008 | 0.194 |
| 15 |
| Fixed | 32.5% | 0.109 | 0.425 | ||
| Caucasian | 7 | 1.06 (0.74–1.51) | Fixed | 0.0% | 0.575 | 0.330 | |
| Asian | 8 | 0.80 (0.60–1.06) | Random | 67.2% | 0.003 | 0.292 | |
| 6 |
| Random | 49.6% | 0.078 | 0.309 | ||
| CC vs. AA+CA | Overall | 18 | 0.86 (0.67–1.10) | Random | 63.6% | <0.001 |
|
| 15 | 0.77 (0.59–1.01) | Random | 59.6% | 0.002 |
| ||
| Caucasian | 7 | 1.05 (0.87–1.26) | Fixed | 2.1% | 0.409 | 0.051 | |
| Asian | 8 | 0.79 (0.44–1.43) | Random | 78.0% | <0.001 | 0.054 | |
| 6 | 0.59 (0.31–1.12) | Random | 67.5% | 0.009 | 0.435 |
OR: odds ratio; CI: confidence interval; SLE: systemic lupus erythematosus.
exclude the studies deviating from Hardy-Weinberg equilibrium.
Meta-analysis of the IL10 −1082/−819/−592 haplotype and SLE.
| Genetic model | Population | Study | OR (95% CI) | Statistical model | I2 |
|
|
| GCC vs. others | Overall | 16 |
| Random | 33.0% | 0.098 | 0.407 |
| 12 |
| Fixed | 36.0% | 0.103 | 0.076 | ||
| Caucasian | 7 |
| Fixed | 40.5% | 0.121 | 0.876 | |
| 6 |
| Random | 49.9% | 0.076 | 0.839 | ||
| Asian | 8 |
| Fixed | 29.3% | 0.194 | 0.600 | |
| 5 | 1.01 (0.75–1.36) | Fixed | 0.0% | 0.450 | 0.124 | ||
| ACC vs. others | Overall | 16 |
| Random | 82.7% | <0.001 | 0.052 |
| 12 |
| Random | 84.4% | <0.001 | 0.350 | ||
| Caucasian | 7 |
| Random | 56.2% | 0.033 | 0.207 | |
| 6 | 0.79 (0.62–1.02) | Random | 59.1% | 0.032 | 0.333 | ||
| 5 | 0.91 (0.77–1.07) | Fixed | 0.0% | 0.446 | 0.206 | ||
| Asian | 8 | 0.74 (0.50–1.12) | Random | 90.2% | <0.001 | 0.191 | |
| 5 | 0.66 (0.31–1.40) | Random | 93.0% | <0.001 | 0.649 | ||
| ATA vs. others | Overall | 16 | 1.14 (0.94–1.39) | Random | 77.7% | <0.001 | 0.073 |
| 12 | 1.21 (0.91–1.60) | Random | 81.1% | <0.001 | 0.331 | ||
| Caucasian | 7 | 0.96 (0.82–1.11) | Fixed | 19.2% | 0.284 | 0.058 | |
| 6 | 0.94 (0.80–1.10) | Fixed | 28.3% | 0.223 | 0.108 | ||
| Asian | 8 | 1.22 (0.87–1.71) | Random | 87.7% | <0.001 | 0.195 | |
| 5 | 1.42 (0.80–2.52) | Random | 89.8% | <0.001 | 0.874 |
OR: odds ratio; CI: confidence interval; SLE: systemic lupus erythematosus.
exclude the studies deviating from Hardy-Weinberg equilibrium.
exclude the study by Sobkowiak (2009).